Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
Alice BoilèveElise MathyCharles RouxMatthieu FaronJulien HadouxLambros TselikasAbir Al GhuzlanSégolène HescotSophie LeboulleuxThierry de BaereLivia LamartinaFrédéric DeschampsEric BaudinPublished in: The Journal of clinical endocrinology and metabolism (2021)
Our results endorse European and French guidelines for stage IV ACC with 2 or fewer tumor organs and favor the combination of mitotane and LRT as first-line treatment. For the first time, a significant number of CRs were observed. Prospective studies are expected to confirm these findings.